LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 6 von insgesamt 6

Suchoptionen

  1. Artikel ; Online: Optimizing cardiac status in the preliver transplant candidate.

    Stachel, Maxine W / DePasquale, Eugene C

    Current opinion in organ transplantation

    2023  Band 29, Heft 1, Seite(n) 50–55

    Abstract: Purpose of review: Liver transplant is a widely accepted therapy for end-stage liver disease. With advances in our understanding of transplant, candidates are increasingly older with more cardiac comorbidities. Cardiovascular disease also represents a ... ...

    Abstract Purpose of review: Liver transplant is a widely accepted therapy for end-stage liver disease. With advances in our understanding of transplant, candidates are increasingly older with more cardiac comorbidities. Cardiovascular disease also represents a leading cause of morbidity and mortality posttransplant.
    Recent findings: Preoperative cardiac risk stratification and treatment may improve short-term and long-term outcomes after liver transplant. Importantly, the appropriate frequency of surveillance has not been defined. Optimal timing of cardiac intervention in end-stage liver disease is likewise uncertain.
    Summary: The approach to risk stratification of cardiovascular disease in end-stage liver disease is outlined, incorporating the AHA/ACC scientific statement on evaluation of cardiac disease in transplant candidates and more recent expert consensus documents. Further study is needed to clarify the ideal timing and approach for cardiovascular interventions.
    Mesh-Begriff(e) Humans ; Cardiovascular Diseases ; End Stage Liver Disease/diagnosis ; End Stage Liver Disease/surgery ; Heart Diseases ; Liver Transplantation/adverse effects ; Heart ; Risk Factors
    Sprache Englisch
    Erscheinungsdatum 2023-11-14
    Erscheinungsland United States
    Dokumenttyp Review ; Journal Article
    ZDB-ID 1390429-2
    ISSN 1531-7013 ; 1087-2418
    ISSN (online) 1531-7013
    ISSN 1087-2418
    DOI 10.1097/MOT.0000000000001119
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: COVID-19 pneumonia in a dual heart-kidney recipient.

    Stachel, Maxine W / Gidea, Claudia G / Reyentovich, Alex / Mehta, Sapna A / Moazami, Nader

    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation

    2020  Band 39, Heft 6, Seite(n) 612–614

    Mesh-Begriff(e) Adult ; Betacoronavirus ; COVID-19 ; Coronavirus Infections ; Humans ; Lopinavir ; Pandemics ; Pneumonia, Viral ; Ritonavir ; SARS-CoV-2
    Chemische Substanzen Lopinavir (2494G1JF75) ; Ritonavir (O3J8G9O825)
    Schlagwörter covid19
    Sprache Englisch
    Erscheinungsdatum 2020-04-18
    Erscheinungsland United States
    Dokumenttyp Letter ; Comment
    ZDB-ID 1062522-7
    ISSN 1557-3117 ; 1053-2498
    ISSN (online) 1557-3117
    ISSN 1053-2498
    DOI 10.1016/j.healun.2020.04.008
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: COVID-19 pneumonia in a dual heart–kidney recipient

    Stachel, Maxine W. / Gidea, Claudia G. / Reyentovich, Alex / Mehta, Sapna A. / Moazami, Nader

    The Journal of Heart and Lung Transplantation

    2020  Band 39, Heft 6, Seite(n) 612–614

    Schlagwörter Surgery ; Pulmonary and Respiratory Medicine ; Transplantation ; Cardiology and Cardiovascular Medicine ; covid19
    Sprache Englisch
    Verlag Elsevier BV
    Erscheinungsland us
    Dokumenttyp Artikel ; Online
    ZDB-ID 1062522-7
    ISSN 1557-3117 ; 1053-2498
    ISSN (online) 1557-3117
    ISSN 1053-2498
    DOI 10.1016/j.healun.2020.04.008
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Long-term follow-up of acute and chronic rejection in heart transplant recipients from hepatitis C viremic (NAT+) donors.

    Stachel, Maxine W / Alimi, Marjan / Narula, Navneet / Flattery, Erin E / Xia, Yuhe / Ramachandran, Abhinay / Saraon, Tajinderpal / Smith, Deane / Reyentovich, Alex / Goldberg, Randal / Kadosh, Bernard S / Razzouk, Louai / Katz, Stuart / Moazami, Nader / Gidea, Claudia G

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

    2022  Band 22, Heft 12, Seite(n) 2951–2960

    Abstract: The long-term safety of heart transplants from hepatitis C viremic (NAT+) donors remains uncertain. We conducted a prospective study of all patients who underwent heart transplantation at our center from January 2018 through August 2020. Routine testing ... ...

    Abstract The long-term safety of heart transplants from hepatitis C viremic (NAT+) donors remains uncertain. We conducted a prospective study of all patients who underwent heart transplantation at our center from January 2018 through August 2020. Routine testing was performed to assess for donor-derived cell-free DNA, acute cellular rejection (ACR), antibody-mediated rejection (AMR), and cardiac allograft vasculopathy (CAV). Allograft dysfunction and mortality were also monitored. Seventy-five NAT- recipients and 32 NAT+ recipients were enrolled in the study. All NAT+ recipients developed viremia detected by PCR, were treated with glecaprevir/pibrentasvir at the time of viremia detection, and cleared the virus by 59 days post-transplant. Patients who underwent NAT testing starting on post-operative day 7 (NAT+ Group 1) had significantly higher viral loads and were viremic for a longer period compared with patients tested on post-operative day 1 (NAT+ Group 2). Through 3.5 years of follow-up, there were no statistically significant differences in timing, severity, or frequency of ACR in NAT+ recipients compared with the NAT- cohort, nor were there differences in noninvasive measures of graft injury, incidence or severity of CAV, graft dysfunction, or mortality. There were five episodes of AMR, all in the NAT- group. There were no statistically significant differences between Group 1 and Group 2 NAT+ cohorts. Overall, these findings underscore the safety of heart transplantation from NAT+ donors.
    Mesh-Begriff(e) Humans ; Follow-Up Studies ; Heart Transplantation/adverse effects ; Hepacivirus ; Hepatitis C ; Prospective Studies ; Tissue Donors ; Transplant Recipients ; Viremia/etiology
    Sprache Englisch
    Erscheinungsdatum 2022-09-20
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2060594-8
    ISSN 1600-6143 ; 1600-6135
    ISSN (online) 1600-6143
    ISSN 1600-6135
    DOI 10.1111/ajt.17190
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: A HCN4+ cardiomyogenic progenitor derived from the first heart field and human pluripotent stem cells.

    Später, Daniela / Abramczuk, Monika K / Buac, Kristina / Zangi, Lior / Stachel, Maxine W / Clarke, Jonathan / Sahara, Makoto / Ludwig, Andreas / Chien, Kenneth R

    Nature cell biology

    2013  Band 15, Heft 9, Seite(n) 1098–1106

    Abstract: Most of the mammalian heart is formed from mesodermal progenitors in the first and second heart fields (FHF and SHF), whereby the FHF gives rise to the left ventricle and parts of the atria and the SHF to the right ventricle, outflow tract and parts of ... ...

    Abstract Most of the mammalian heart is formed from mesodermal progenitors in the first and second heart fields (FHF and SHF), whereby the FHF gives rise to the left ventricle and parts of the atria and the SHF to the right ventricle, outflow tract and parts of the atria. Whereas SHF progenitors have been characterized in detail, using specific molecular markers, comprehensive studies on the FHF have been hampered by the lack of exclusive markers. Here, we present Hcn4 (hyperpolarization-activated cyclic nucleotide-gated channel 4) as an FHF marker. Lineage-traced Hcn4+/FHF cells delineate FHF-derived structures in the heart and primarily contribute to cardiomyogenic cell lineages, thereby identifying an early cardiomyogenic progenitor pool. As a surface marker, HCN4 also allowed the isolation of cardiomyogenic Hcn4+/FHF progenitors from human embryonic stem cells. We conclude that a primary purpose of the FHF is to generate cardiac muscle and support the contractile activity of the primitive heart tube, whereas SHF-derived progenitors contribute to heart cell lineage diversification.
    Mesh-Begriff(e) Animals ; Biomarkers/metabolism ; Cell Differentiation ; Cell Lineage ; Cyclic Nucleotide-Gated Cation Channels/genetics ; Cyclic Nucleotide-Gated Cation Channels/metabolism ; Embryo, Mammalian ; Embryonic Stem Cells/cytology ; Embryonic Stem Cells/metabolism ; Gene Expression Regulation, Developmental ; Heart Atria/cytology ; Heart Atria/embryology ; Heart Atria/metabolism ; Heart Ventricles/cytology ; Heart Ventricles/embryology ; Heart Ventricles/metabolism ; Humans ; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels ; Mesoderm/cytology ; Mesoderm/metabolism ; Mice ; Morphogenesis ; Muscle Proteins/genetics ; Muscle Proteins/metabolism ; Myocardium/cytology ; Myocardium/metabolism ; Myocytes, Cardiac/cytology ; Myocytes, Cardiac/metabolism ; Pluripotent Stem Cells/cytology ; Pluripotent Stem Cells/metabolism ; Potassium Channels
    Chemische Substanzen Biomarkers ; Cyclic Nucleotide-Gated Cation Channels ; HCN4 protein, human ; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels ; Muscle Proteins ; Potassium Channels
    Sprache Englisch
    Erscheinungsdatum 2013-08-25
    Erscheinungsland England
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1474722-4
    ISSN 1476-4679 ; 1465-7392
    ISSN (online) 1476-4679
    ISSN 1465-7392
    DOI 10.1038/ncb2824
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang